HTG Molecular Diagnostics (HTGM) Key Ratios
$0.35
As on 16-Aug-2023 09:30EDT
Market cap
$1 Mln
Revenue (TTM)
$6 Mln
P/E Ratio
--
P/B Ratio
6.3
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -57.67 | -12.83 | -28.21 | -30.14 | -18.75 |
| EBIT | -12.04 | 18.47 | -11.59 | -2.63 | -2.94 |
| Net Profit | -7.72 | 22.20 | -7.48 | -1.34 | -1.82 |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-22 | Dec-21 |
| EBIT-Margin
| -252.14 | -185.49 | -319.30 | -327.19 | -200.11 |
| Net Margin
| -251.34 | -141.03 | -324.28 | -- | -- |
| Return on equity
| -173.28 | -157.60 | -2,394.91 | -273.49 | -137.80 |
| Return on Capital
| -90.05 | -73.86 | -- | -133.57 | -69.64 |
| Return on Assets
| -64.58 | -57.55 | -74.11 | -89.53 | -52.23 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.90 | 1.13 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
--
|
-133.57
|
-69.64
|
-66.94
|
-43.52
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-2,394.91
Lower than Peers by 2,399.86
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
-2,394.91
|
-273.49
|
-137.80
|
-108.55
|
-85.65
|
|
Peer Median
|
4.94
|
--
|
--
|
--
|
--
|
ROA
-74.11
Lower than Peers by 76.56
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
-74.11
|
-89.53
|
-52.23
|
-51.97
|
-43.42
|
|
Peer Median
|
2.45
|
--
|
--
|
--
|
--
|
EBIT Margin
-319.30
Lower than Peers by 327.77
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
-319.30
|
-327.19
|
-200.11
|
-229.10
|
-98.73
|
|
Peer Median
|
8.47
|
--
|
--
|
--
|
--
|
Net Margin
-324.28
Lower than Peers by 328.96
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
-324.28
|
-339.20
|
-192.49
|
-251.34
|
-97.33
|
|
Peer Median
|
4.68
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
-28.21
Lower than Peers by 36.69
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
-28.21
|
-0.29
|
0.04
|
-0.55
|
-0.11
|
|
Peer Median
|
8.49
|
--
|
--
|
--
|
--
|
EBIT Growth
-11.59
Lower than Peers by 22.24
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
-11.59
|
-16.86
|
9.00
|
-3.30
|
-21.94
|
|
Peer Median
|
10.65
|
--
|
--
|
--
|
--
|
Net Profit Growth
-7.48
Lower than Peers by 21.03
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
-7.48
|
-25.95
|
17.85
|
-8.15
|
-17.28
|
|
Peer Median
|
13.55
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
--
|
0.90
|
1.13
|
0.87
|
0.47
|
|
Peer Median
|
0.40
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
7.50
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
7.50
|
0.80
|
0.54
|
0.26
|
0.16
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.40
Lower than Peers by 1.42
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
1.40
|
1.89
|
2.73
|
4.54
|
4.65
|
|
Peer Median
|
2.83
|
--
|
--
|
--
|
--
|
Quick Ratio
1.30
Lower than Peers by 0.74
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
1.30
|
1.78
|
2.53
|
4.34
|
4.51
|
|
Peer Median
|
2.05
|
--
|
--
|
--
|
--
|
Interest Coverage
-26.00
Lower than Peers by 30.96
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
-26.00
|
-24.31
|
-16.74
|
-19.11
|
-19.80
|
|
Peer Median
|
4.96
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
18.22
Higher than Peers by 1.76
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
18.22
|
22.33
|
23.49
|
18.58
|
16.48
|
|
Peer Median
|
16.46
|
--
|
--
|
--
|
--
|
Asset Turnover
0.23
Lower than Peers by 0.27
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
0.23
|
0.26
|
0.27
|
0.21
|
0.43
|
|
Peer Median
|
0.50
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
--
|
100.81
|
75.48
|
101.53
|
77.76
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
--
|
115.72
|
155.19
|
126.36
|
52.80
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
--
|
112.12
|
133.71
|
137.78
|
71.98
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
--
|
104.41
|
96.96
|
90.12
|
58.57
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Book Value
6.26
Higher than Peers by 2.47
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
6.26
|
--
|
--
|
--
|
--
|
|
Peer Median
|
3.79
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-0.35
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
-0.35
|
0.37
|
0.52
|
0.89
|
1.31
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
1
Lower than Peers by 539
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
1
|
--
|
--
|
--
|
--
|
|
Peer Median
|
540
|
--
|
--
|
--
|
--
|